Kissei Pharmaceutical News

Kissei Pharmaceutical: Launch of YSELTY (generic name linzagolix) for uterine fibroid treatment in Europe

Sep 16 19:45 ET

Kissei Pharmaceutical: Announcement of the new sale of the uterine fibroid treatment drug Iserti (generic name Linzagolix) in Europe

Sep 16 19:45 ET

Kissei Pharmaceutical: Drug discovery research collaboration agreement with Reborna Biosciences, Inc.

Sep 9 01:00 ET

Kissei Pharmaceutical: Announcement of the conclusion of a drug discovery joint research agreement with Livorna Biosciences

Sep 9 01:00 ET

Kissei Pharmaceutical: Licensing Agreement for "olutasidenib", an Acute Myeloid Leukemia Drug

Sep 3 19:45 ET

Kissei Pharmaceutical: Notice of conclusion of a technology introduction agreement for the acute myeloid leukemia agent “ortacidenib”

Sep 3 19:45 ET

Kissei Pharmaceutical: Supplementary explanatory materials related to the financial statements for the three-month period ending on June 30, 2024.

Jul 30 02:00 ET

Kissei Pharmaceutical: Supplementary financial data for the first quarter of the March 2025 period.

Jul 30 02:00 ET

Kissei Pharmaceutical: Consolidated financial results for the three months ending on June 30, 2024 [Japanese standards]

Jul 30 02:00 ET

Kissei Pharmaceutical: Short message of Q1 financial results for March 2025 (consolidated, Japanese standard).

Jul 30 02:00 ET

Kissei Pharmaceutical: Report on Corporate Governance, June 28th, 2024.

Jun 28 00:59 ET

Kissei Pharmaceutical: Extraordinary Report

Jun 28 00:00 ET

Kissei Pharmaceutical: Internal Control Report - 79th period (Apr. 1, 2023 to Mar. 31, 2024)

Jun 25 00:01 ET

Kissei Pharmaceutical: Securities Report - 79th Fiscal Year (April 1, 2023 - March 31, 2024)

Jun 25 00:00 ET

Kissei Pharmaceutical: Confirmation letter

Jun 25 00:00 ET

Kissei Pharmaceutical: Announcements of individual stocks: Notice of signing a technology transfer contract with JW Pharma Co., Ltd. (South Korea) for Linzagolix.

Jun 10 03:00 ET

Kissei Pharmaceutical: Licensing agreement for GnRH antagonist Linzagolix with South Korean pharmaceutical company JW Pharmaceuticals.

Jun 10 03:00 ET

Kissei Pharmaceutical: Notice of the 2024 Convocation Annual General Meeting

Jun 2 19:00 ET

Kissei Pharmaceutical: 2024 Annual General Meeting of Shareholders Convocation Notice

Jun 2 19:00 ET

Kissei Pharmaceutical: Independent Officer Notification Form

May 31 02:00 ET